Nexalin Technology, Inc., a pioneer in neurostimulation technology, has released its 2024 10-K report, detailing significant financial and operational developments. The company, known for its innovative bioelectronic medical devices aimed at treating mental health conditions such as anxiety, insomnia, and depression, has made notable strides in product development, regulatory approvals, and market expansion.
Financial Highlights
Revenues, net: $168,721, primarily from the sale of devices, supplies, and licensing and treatment fee agreements. The increase in revenue for the year ended December 31, 2024, compared to 2023, was primarily due to sales of supplies and parts.
Gross Profit: $132,128, yielding a gross margin of 78%, which remained consistent year over year.
Loss from operations: $(7,754,646), an increase of 36% from the previous year, primarily due to increased operating expenses.
Net loss: $(7,607,182), an increase of 64% from the previous year, driven by higher operating expenses and a decrease in other income.
Comprehensive loss: $(7,607,290), reflecting a 62% increase from the previous year, influenced by the same factors affecting net loss.
Business Highlights
Product Development: Nexalin has developed innovative neurostimulation products, including the Gen-1, Gen-2, and Gen-3 devices, which utilize bioelectronic medical technology to treat anxiety, insomnia, and depression without drugs or psychotherapy.
Regulatory Status: The Gen-1 device is classified as a Class II device by the FDA for treating anxiety and insomnia. The Gen-2 and Gen-3 devices are undergoing FDA review, with plans for clinical trials in the U.S., Brazil, and China starting in 2025.
Technological Advancements: The Gen-2 and Gen-3 devices feature a new advanced waveform technology emitted at 15 milliamps, believed to penetrate deeper into the brain to stimulate structures associated with mental illness, potentially enhancing patient response without side effects.
International Approvals: The Gen-2 device has received approval from the China National Medical Products Administration for treating insomnia and depression, and regulatory approval in Brazil.
Joint Venture in China: A joint venture with Wider Come Limited has been established to market and distribute Gen-2 devices in China and other regions, with Wider funding initial operations.
Virtual Clinic Development: Nexalin is developing a virtual clinic platform to allow physicians to diagnose and prescribe treatments remotely, enhancing privacy and convenience for patients.
Market Expansion: The company is focusing on expanding its market presence by leveraging its advanced technology to disrupt traditional mental health treatment models, aiming to replace expensive psychotherapy and pharmaceuticals.
Future Outlook: Nexalin plans to conduct additional clinical trials and pursue regulatory approvals to expand the use of its devices for various mental health conditions, including depression, substance use disorders, and chronic pain.
Strategic Initiatives
Strategic Initiatives: Nexalin Technology, Inc. is focusing on the development and commercialization of its Gen-2 and Gen-3 neurostimulation devices. The company is actively pursuing regulatory approvals in the U.S. and other territories, including the European Union, Brazil, and China. A joint venture was established with Wider Come Limited to market and sell Gen-2 devices in China, with Wider funding initial operations. The company is also exploring virtual clinic platforms to enhance patient privacy and treatment accessibility.
Capital Management: The company has been managing its capital through equity sales, raising approximately $4.5 million from a stock offering in July 2024. It has not declared or paid any dividends and does not plan to do so in the foreseeable future. The company has a significant accumulated deficit and continues to incur operating losses, primarily funding these through equity sales. As of December 31, 2024, the company had cash and cash equivalents of $574,485 and short-term investments of $2,905,438.
Future Outlook: Nexalin plans to continue its strategic focus on obtaining FDA clearance for its Gen-3 device and expanding its market presence in the U.S. and internationally. The company aims to address the global mental health epidemic with its innovative devices and is preparing for clinical trials in the U.S., Brazil, and China. The company anticipates ongoing operating losses as it executes its development plans through 2025 and will need to raise additional capital to support its initiatives.
Challenges and Risks
Financial Risks: The company faces significant financial risks due to its history of substantial losses and the expectation of continued losses in the coming years. The company’s limited operating history and reliance on external financing, including equity offerings, pose challenges to achieving profitability. The company’s ability to continue as a going concern is in doubt, as highlighted by the independent accountant’s audit report, which emphasizes the need for successful execution of the business plan and potential additional financing.
Operational Risks: The company is in the early stages of product development, with significant expenses anticipated for ongoing and planned preclinical and clinical development, regulatory approvals, and commercialization efforts. The uncertainty in product development timelines and costs, coupled with potential regulatory hurdles, adds to the financial risks. Operational risks include the company’s dependence on third parties for clinical trials and quality assurance, which may not perform satisfactorily, leading to delays or increased costs. The company also faces challenges in transitioning from a research-focused entity to one capable of supporting commercial activities, which may involve significant growth in personnel and infrastructure.
Regulatory Risks: Regulatory risks are prominent, with the company’s products subject to FDA reclassification and potential changes in classification that could impact development costs and timelines. The company also faces risks related to conducting business in China, including regulatory changes, enforcement risks, and potential difficulties in enforcing legal rights.
Management’s Discussion and Analysis: Management acknowledges the need for additional funding to meet financial needs and pursue business objectives. The company is not currently cash flow positive and may require substantial additional funding for ongoing operations and planned activities. Management is aware of the risks associated with raising additional capital, including potential dilution of stockholders’ interests and restrictive covenants in financing agreements.
Market Risks: The company is exposed to market risks, including foreign currency exchange rate fluctuations, which could adversely affect financial results. The company’s operations in China and potential regulatory changes in the region add to the market risks, with potential impacts on supply chain and cost structures.
Overall, the company faces a complex landscape of financial, operational, and regulatory challenges that require careful management and strategic planning to navigate successfully.
SEC Filing: Nexalin Technology, Inc. [ NXL ] – 10-K – Mar. 14, 2025
